SCTXScribe Therapeutics, Inc.同业对比
Scribe Therapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCTX本股 | $620M#1 | — | — | — | — | — | — | — | — | — | — | — |
| CRDF | $100M#2 | — | 3.8x#8 | 169.2x#6 | -13.2%#5 | -0.9%#4 | -8256.3%#6 | -0.2%#4 | — | — | -35.8%#10 | — |
| ATRA | $100M#3 | — | — | 0.8x#2 | -6.3%#4 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#4 | — |
| PTHS | $81M#4 | — | — | 4.8x#4 | — | -444.6%#14 | -193.1%#4 | — | — | — | -33.0%#9 | — |
| VXRT | $80M#5 | 2.0x#1 | 1.0x#2 | 0.3x#1 | 726.7%#1 | 124.4%#2 | 7.6%#2 | 0.0%#1 | 22.5%#1 | — | -24.0%#6 | — |
| KLRS | $76M#6 | — | 1.3x#3 | 463.1x#7 | — | 37.2%#3 | -27970.9%#8 | -75.3%#7 | — | — | -27.8%#8 | — |
| ELOX | $75M#7 | 5.2x#2 | 1.6x#4 | — | -100.0%#7 | -90.7%#11 | — | -12.9%#5 | — | — | — | — |
| BSEM | $74M#8 | — | 2.7x#6 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LONA | $68M#10 | — | 2.0x#5 | — | — | -9.3%#5 | — | -315.5%#10 | — | — | 93.0%#2 | — |
| CSBR | $69M#9 | — | 17.6x#10 | 1.2x#3 | 4.4%#3 | -125.0%#13 | -1.9%#3 | -0.0%#3 | — | — | -25.5%#7 | — |
| EXOZ | $60M#11 | — | 16.5x#9 | 861.0x#8 | — | -56.3%#10 | -13867.0%#7 | -250.6%#9 | — | — | -45.8%#12 | — |
| INMB | $59M#13 | — | 2.9x#7 | 1174.0x#9 | 257.1%#2 | -9.5%#6 | -94766.0%#9 | -225.9%#8 | -607.3%#2 | — | 10.2%#3 | — |
| INKT | $59M#12 | — | — | — | — | -15.9%#7 | — | — | — | — | -19.2%#5 | — |
| IMA | $59M#14 | — | 0.4x#1 | 73.4x#5 | -77.1%#6 | -24.0%#8 | -6056.4%#5 | -31.9%#6 | — | — | -39.1%#11 | — |
| BKHAU | $53M#15 | — | — | — | — | -30.6%#9 | — | — | — | — | 133.8%#1 | 96.2%#1 |
| TVGN | $50M#16 | — | — | — | — | -91.4%#12 | — | — | — | — | -81.8%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议